166 related articles for article (PubMed ID: 36999444)
1. Ophiopogonin D attenuates the progression of murine systemic lupus erythematosus by reducing B cell numbers.
Nie Y; Li C; Sun N
J Biochem Mol Toxicol; 2023 Jul; 37(7):e23361. PubMed ID: 36999444
[TBL] [Abstract][Full Text] [Related]
2. Staphylococcus aureus peptidoglycan (PGN) induces pathogenic autoantibody production via autoreactive B cell receptor clonal selection, implications in systemic lupus erythematosus.
Ning W; Cheng D; Howe PH; Bian C; Kamen DL; Luo Z; Fu X; Ogunrinde E; Yang L; Wang X; Li QZ; Oates J; Zhang W; White D; Wan Z; Gilkeson GS; Jiang W
J Autoimmun; 2022 Jul; 131():102860. PubMed ID: 35810689
[TBL] [Abstract][Full Text] [Related]
3. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
[TBL] [Abstract][Full Text] [Related]
4. TIGIT-Fc fusion protein alleviates murine lupus nephritis through the regulation of SPI-B-PAX5-XBP1 axis-mediated B-cell differentiation.
Zhao J; Li L; Feng X; Gao C; Gao L; Zhan Y; Wang Z; Zhao M; Yin H; Lu Q
J Autoimmun; 2023 Sep; 139():103087. PubMed ID: 37481835
[TBL] [Abstract][Full Text] [Related]
5. Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice.
Yan SX; Deng XM; Wang QT; Sun XJ; Wei W
Acta Pharmacol Sin; 2015 Nov; 36(11):1367-76. PubMed ID: 26456588
[TBL] [Abstract][Full Text] [Related]
6. IgG4 Autoantibodies Attenuate Systemic Lupus Erythematosus Progression by Suppressing Complement Consumption and Inflammatory Cytokine Production.
Pan Q; Xiao H; Shi L; He Y; Cai J; Wu J; Li A; Ye L; Yang C; Liu HF
Front Immunol; 2020; 11():1047. PubMed ID: 32625200
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody therapy that targets phospholipid-binding protein delays lupus activity in MRL/lpr mice.
Mihaylova N; Bradyanova S; Chipinski P; Chausheva S; Kyurkchiev D; Tchorbanov AI
Scand J Immunol; 2020 Sep; 92(3):e12915. PubMed ID: 32533866
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of glutaminolysis ameliorates lupus by regulating T and B cell subsets and downregulating the mTOR/P70S6K/4EBP1 and NLRP3/caspase-1/IL-1β pathways in MRL/lpr mice.
Zhang X; Wang G; Bi Y; Jiang Z; Wang X
Int Immunopharmacol; 2022 Nov; 112():109133. PubMed ID: 36113317
[TBL] [Abstract][Full Text] [Related]
9. B cell and/or autoantibody deficiency do not prevent neuropsychiatric disease in murine systemic lupus erythematosus.
Wen J; Doerner J; Chalmers S; Stock A; Wang H; Gullinello M; Shlomchik MJ; Putterman C
J Neuroinflammation; 2016 Apr; 13(1):73. PubMed ID: 27055816
[TBL] [Abstract][Full Text] [Related]
10. Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis.
Jiang C; Zhao ML; Scearce RM; Diaz M
Arthritis Rheum; 2011 Apr; 63(4):1086-96. PubMed ID: 21225690
[TBL] [Abstract][Full Text] [Related]
11. A benzenediamine derivative fc-99 attenuates lupus-like syndrome in MRL/lpr mice related to suppression of pDC activation.
Ji J; Fan H; Li F; Li X; Dong G; Gong W; Song Y; Liu F; Hua C; Tan R; Dou H; Hou Y
Immunol Lett; 2015 Dec; 168(2):355-65. PubMed ID: 26545567
[TBL] [Abstract][Full Text] [Related]
12. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice.
Elliott MK; Jarmi T; Ruiz P; Xu Y; Holers VM; Gilkeson GS
Kidney Int; 2004 Jan; 65(1):129-38. PubMed ID: 14675043
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effects of artesunate on lupus-prone MRL/lpr mice are dependent on T follicular helper cell differentiation and activation of JAK2-STAT3 signaling pathway.
Dang WZ; Li H; Jiang B; Nandakumar KS; Liu KF; Liu LX; Yu XC; Tan HJ; Zhou C
Phytomedicine; 2019 Sep; 62():152965. PubMed ID: 31129432
[TBL] [Abstract][Full Text] [Related]
14. HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus.
Kim YY; Park KT; Jang SY; Lee KH; Byun JY; Suh KH; Lee YM; Kim YH; Hwang KW
Arthritis Res Ther; 2017 Sep; 19(1):211. PubMed ID: 28950886
[TBL] [Abstract][Full Text] [Related]
15. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF).
Zhou L; Sun L; Wu H; Zhang L; Chen M; Liu J; Zhong R
Eur J Pharmacol; 2013 Sep; 715(1-3):230-7. PubMed ID: 23712004
[TBL] [Abstract][Full Text] [Related]
16. Prolactin promotes proliferation of germinal center B cells, formation of plasma cells, and elevated levels of IgG3 anti-dsDNA autoantibodies.
Carreón-Talavera R; Santana-Sánchez P; Fuentes-Pananá EM; Legorreta-Haquet MV; Chávez-Sánchez L; Gorocica-Rosete PS; Chávez-Rueda AK
Front Immunol; 2022; 13():1017115. PubMed ID: 36389691
[TBL] [Abstract][Full Text] [Related]
17. Interferon regulatory factor-5 deficiency ameliorates disease severity in the MRL/lpr mouse model of lupus in the absence of a mutation in DOCK2.
Yasuda K; Watkins AA; Kochar GS; Wilson GE; Laskow B; Richez C; Bonegio RG; Rifkin IR
PLoS One; 2014; 9(7):e103478. PubMed ID: 25076492
[TBL] [Abstract][Full Text] [Related]
18. Anti-ANX A1 Antibody Therapy in MRL/lpr Murine Model of Systemic Lupus Erythematosus.
Bradyanova S; Mihaylova N; Chipinski P; Manassiev Y; Herbáth M; Kyurkchiev D; Prechl J; Tchorbanov AI
Arch Immunol Ther Exp (Warsz); 2021 Jul; 69(1):19. PubMed ID: 34322760
[TBL] [Abstract][Full Text] [Related]
19. Abrogation of skin disease in LUPUS-prone MRL/FASlpr mice by means of a novel tylophorine analog.
Choi JY; Gao W; Odegard J; Shiah HS; Kashgarian M; McNiff JM; Baker DC; Cheng YC; Craft J
Arthritis Rheum; 2006 Oct; 54(10):3277-83. PubMed ID: 17009262
[TBL] [Abstract][Full Text] [Related]
20. Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus.
Lee J; Park Y; Jang SG; Hong SM; Song YS; Kim MJ; Baek S; Park SH; Kwok SK
Front Immunol; 2021; 12():704526. PubMed ID: 34497607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
